{"_id": "650d0d33c9669d2e208ec2c8", "booleanRepresentation": "{\n    \"$and\":[\n        {\n            \"$and\": [\n                {\"histologically- or cytologically-confirmed adenocarcinoma of the prostate without small cell histology\"},\n                {\"prostate cancer progression while on androgen deprivation therapy (or post bilateral orchiectomy) within 6 months prior to randomization\"},\n                {\"current evidence of metastatic disease documented by either bone lesions on bone scan and/or soft tissue disease by computed tomography/magnetic resonance imaging (CT/MRI)\"},\n                {\n                    \"$or\": [\n                        {\"abiraterone acetate exposure\": \"abiraterone-na\u00efve\"},\n                        {\"abiraterone acetate exposure\": \"received prior abiraterone acetate for the treatment of mHSPC or mCRPC, for a minimum of 4 weeks and not progressed while on treatment\"},\n                        {\"abiraterone acetate exposure\": \"received prior abiraterone acetate for the treatment of mHSPC or mCRPC and progressed on treatment after a minimum of 8 weeks treatment (minimum 14 weeks for those with bone progression)\"}\n                    ]\n                },\n                {\"ongoing androgen deprivation with serum testosterone <50 ng/dL (<2.0 nM)\"},\n                {\"participants receiving bone resorptive therapy (including, but not limited to, bisphosphonate or denosumab) must have been on stable doses prior to randomization\"},\n                {\n                    \"$and\": [\n                        {\"participants must agree to the following during the study treatment period and for at least 90 days after the last dose of enzalutamide\": \"refrain from donating sperm\"},\n                        {\n                            \"$or\": [\n                                {\"participants must agree to the following during the study treatment period and for at least 90 days after the last dose of enzalutamide\": \"be abstinent\"},\n                                {\"participants must agree to the following during the study treatment period and for at least 90 days after the last dose of enzalutamide\": \"must agree to use male condom\"}\n                            ]\n                        }\n                    ]\n                },\n                {\n                    \"$or\": [\n                        {\"provided newly obtained core or excisional biopsy (obtained within 12 months of screening) from soft tissue not previously irradiated (samples from tumors progressing in a prior site of radiation are allowed)\"},\n                        {\"provided newly obtained bone biopsy sample (for participants with bone only or bone predominant disease)\"}\n                    ]\n                },\n                {\"Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 assessed within 7 days of randomization\"}\n            ]\n        },\n        {\n            \"$not\": {\n                \"$or\": [\n                    {\"known additional malignancy that is progressing or has required active treatment in the last 3 years\"},\n                    {\"active autoimmune disease that has required systemic treatment in past 2 years\"},\n                    {\"diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy\"},\n                    {\"undergone major surgery including local prostate intervention (excluding prostate biopsy) within 28 days prior to randomization and not recovered adequately from the toxicities and/or complications\"},\n                    {\"gastrointestinal disorder affecting absorption or is unable to swallow tablets/capsules\"},\n                    {\"active infection (including tuberculosis) requiring systemic therapy\"},\n                    {\"history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease\"},\n                    {\"known active human immunodeficiency virus (HIV), concurrent active hepatitis B virus (HBV) or known active hepatitis C virus (HCV) infection\"},\n                    {\"known active central nervous system (CNS) metastases and/or carcinomatous meningitis\"},\n                    {\"hypersensitivity to pembrolizumab and/or enzalutamide and/or any of their excipients\"},\n                    {\"history of seizure or any condition that may predispose to seizure\"},\n                    {\"history of loss of consciousness within 12 months of screening\"},\n                    {\"hypotension (systolic blood pressure <86 millimeters of mercury [mmHg]) or uncontrolled hypertension (systolic blood pressure >170 mmHg or diastolic blood pressure >105 mmHg) at the screening visit\"},\n                    {\"bradycardia (heart rate of <50 beats per minute) on the screening electrocardiogram (ECG)\"},\n                    {\"history of prostate cancer progression on ketoconazole\"},\n                    {\"prior treatment with enzalutamide, apalutamide, darolutamide or cytochrome P450 (CYP) 17 inhibitor other than abiraterone acetate\"},\n                    {\"prior therapy with an anti-programmed cell death-1 (anti-PD-1), anti-programmed cell death-ligand 1 (anti-PD-L1), or anti-PD-L2 agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor\"},\n                    {\"prior treatment with radium or other therapeutic radiopharmaceuticals for prostate cancer\"},\n                    {\"prior treatment with docetaxel or another chemotherapy agent for mCRPC\"},\n                    {\"prior anti-cancer monoclonal antibody (mAb) prior to randomization\"},\n                    {\"used herbal products that may have hormonal anti-prostate cancer activity and/or are known to decrease PSA levels (eg, saw palmetto) prior to randomization\"},\n                    {\"received a live or live attenuated vaccine within 30 days prior to randomization\"},\n                    {\"currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment\"},\n                    {\"has a 'superscan' bone scan\"},\n                    {\"expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 90 days after the last dose of enzalutamide\"},\n                    {\"had an allogenic tissue/solid organ transplant\"}\n                ]\n            }\n        }\n    ]\n}", "nctId": "NCT03834493", "title": "A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)"}